Literature DB >> 20483719

Fusion proteins for versatile antigen targeting to cell surface receptors reveal differential capacity to prime immune responses.

Roland Kratzer1, François-Xavier Mauvais, Anne Burgevin, Emilie Barilleau, Peter van Endert.   

Abstract

Targeting of proteins to APCs is an attractive strategy for eliciting adaptive immune responses. However, the relationship between the choice of the targeted receptor and the quality and quantity of responses remains poorly understood. We describe a strategy for expression of Ags including hydrophobic proteins as soluble fusion proteins that are optimized for proteasome-dependent MHC class I-restricted cross-presentation and form stable complexes with a wide variety of targeting Abs. Upon s.c. immunization, these complexes were initially taken up by CD169+ lymph node subcapsular sinus macrophages. In the OVA model system, receptor-targeted antigenic complexes primed specific T and B cell responses in vitro and in vivo at least 100-fold more efficiently than Ag alone. Comparison of 10 targeting receptors allowed us to establish a ranking with respect to priming of CD8+ T cell responses and demonstrated striking differences with respect to the relative efficacy of CD8+ and CD4+ T cell subset and B cell priming. The described fusion proteins should help in developing optimized strategies for targeted delivery of protein Ags in the context of tolerization or vaccination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483719     DOI: 10.4049/jimmunol.0902555

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen.

Authors:  Nawel Merzougui; Roland Kratzer; Loredana Saveanu; Peter van Endert
Journal:  EMBO Rep       Date:  2011-12-01       Impact factor: 8.807

Review 2.  B cell follicles and antigen encounters of the third kind.

Authors:  Jason G Cyster
Journal:  Nat Immunol       Date:  2010-10-19       Impact factor: 25.606

Review 3.  Cross-presentation by dendritic cells.

Authors:  Olivier P Joffre; Elodie Segura; Ariel Savina; Sebastian Amigorena
Journal:  Nat Rev Immunol       Date:  2012-07-13       Impact factor: 53.106

4.  Porcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophages.

Authors:  Peter L Delputte; Hanne Van Gorp; Herman W Favoreel; Inge Hoebeke; Iris Delrue; Hannah Dewerchin; Frank Verdonck; Bruno Verhasselt; Eric Cox; Hans J Nauwynck
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

Review 5.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

6.  Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response.

Authors:  Haiyan Li; Yuhuan Li; Jun Jiao; Hong-Ming Hu
Journal:  Nat Nanotechnol       Date:  2011-09-18       Impact factor: 39.213

7.  Development of a recombinant antibody to target peptides and proteins to sialoadhesin-expressing macrophages.

Authors:  Karen Ooms; Hanne Van Gorp; Tim Van Gaever; Hans J Nauwynck; Peter L Delputte
Journal:  BMC Biotechnol       Date:  2013-04-10       Impact factor: 2.563

8.  Targeting Dendritic Cells in vivo for Cancer Therapy.

Authors:  Irina Caminschi; Eugene Maraskovsky; William Ross Heath
Journal:  Front Immunol       Date:  2012-02-07       Impact factor: 7.561

9.  The role of insulin-regulated aminopeptidase in MHC class I antigen presentation.

Authors:  Loredana Saveanu; Peter van Endert
Journal:  Front Immunol       Date:  2012-03-21       Impact factor: 7.561

10.  ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes.

Authors:  Émmanuelle Énée; Roland Kratzer; Jean-Baptiste Arnoux; Emilie Barilleau; Yamina Hamel; Christophe Marchi; Jacques Beltrand; Bénédicte Michaud; Lucienne Chatenoud; Jean-Jacques Robert; Peter van Endert
Journal:  Diabetes       Date:  2012-05-14       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.